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Background
Recombinant MVA expressing HIV genes are currently
being tested in phase I and II vaccine trials. During efforts
to make rMVA/HIV candidate vaccines, we found variable
stability of inserted gene expression. Maintaining stability
upon repeated passage for vaccine production while keep-
ing high expression of inserted gene for increased immu-
nogenicity is highly desirable. In continuation of efforts to
improve stability, we now compare three insertion sites in
the MVA genome using the same HIV env gene.
Methods
Clade D HIV/UGD env gene controlled by vaccinia mH5
promoter was inserted into three regions of the MVA
genome, differing in importance of the flanking DNA for
vaccinia virus replication. rMVA viruses expressing this
HIV Env were made and analyzed for stability and growth
after serial passage by immunostaining.
Results
We analyzed three insertion sites for an HIV env in MVA:
del II and del III sites and between essential genes I8/G1.
Large deletions of HIV env and MVA flanks resulted from
repeated passages of rMVA/HIV Env in del II region with
overgrowth of non-expressing virus, indicating that del II
is a problematic insertion site. Analysis of genes flanking
this region identified no essential genes or genes affecting
viral replication, providing a large target for viable dele-
tion mutations. HIV env inserted between I8/G1 essential
genes resulted in stable rMVA virus, since deletions
extending into the essential MVA flanks would not be via-
ble. MVA del III region analysis determined genes
adversely affecting virus replication within 1-2 kbp flank-
ing the insertion site. A vector was constructed that
removed intervening non-essential sequences flanking the
insertion site. rMVA/HIV Env made with this vector dem-
onstrated env gene stability in this restructured del III site.
Conclusion
For more stable rMVA construction, insert genes between
essential genes or genes affecting viral replication. Avoid
sites between non-essential genes that provide targets for
viable deletions.
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